## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 13.4% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-16.9% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($55.70)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)**
- Source: Business Wire | 20251215T210936 | Neutral | Relevance: 100%
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced that its Board of Directors approved inducement grants for 78 new employees on December 12, 2025. These grants, totaling up to 141,310 restricted stock units, are issued under NASDAQ Listing Rule 5635(c)(4) and vest annually over four years, operating outside the company's existing equity incentive plans.

**2. Arrowhead climbs to 52-week high as RNAi bets pay off**
- Source: Longevity.Technology | 20251215T170950 | Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals has experienced a dramatic turnaround in 2025, reaching a 52-week high after its RNA interference (RNAi) drug, Redemplo (plozasiran), received FDA approval for familial chylomicronemia syndrome (FCS) and Breakthrough Therapy designation for severe hypertriglyceridemia (SHTG). The company's stock has more than tripled in value over the past year, reflecting investor confidence in its validated RNAi platform, expanding pipeline into broader markets like Alzheimer's disease, and significant partnerships with major pharmaceutical companies. Despite ongoing patent litigation and clinical trial risks, Arrowhead's recent successes have solidified its position as a commercial-stage biotech player.

**3. Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approval, Plozasiran Breakthrough Status and ARO-MAPT Trial Progress**
- Source: Simply Wall Street | 20251215T040950 | Somewhat-Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals (ARWR) has seen significant clinical and regulatory progress with the FDA approval of REDEMPLO, Breakthrough Therapy status for plozasiran, and the advancement of ARO-MAPT into human trials. These developments have led to substantial share price increases, with the stock currently trading above analyst targets. Despite this positive momentum, Simply Wall St assesses the company as 22% overvalued with a fair value of $57.67, highlighting a debate over whether current growth is already priced in.

**4. 36,469 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Marex Group plc**
- Source: MarketBeat | 20251215T110950 | Somewhat-Bullish | Relevance: 100%
- Marex Group plc recently acquired 36,469 shares of Arrowhead Pharmaceuticals, Inc. ($ARWR) during the second quarter, valued at approximately $576,000, bringing institutional ownership to about 62.61%. Analysts have a "Moderate Buy" consensus with an average price target of $58.56, but company insiders have been selling shares, reducing their ownership to 4.30%. The biotechnology company currently trades near $70 with a market capitalization around $9.5 billion.

**5. Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 7.6% - What's Next?**
- Source: MarketBeat | 20251216T172336 | Somewhat-Bearish | Relevance: 99%
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares dropped 7.6% during Tuesday's mid-day trading. Despite a "Moderate Buy" consensus from analysts with several firms raising price targets, the stock saw reduced trading volume and insider selling totaling approximately $2.19 million over the past 90 days. Institutional investors, led by Vanguard, hold a significant stake in the company.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |
| 2025-12-01 | B of A Securiti | $62 | $42 | +48% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |
| 2025-12-01 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($2.19M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Elevated short interest (11.3%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +37%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -27% YoY, concerning. Analyst sentiment positive (8 raises, avg +37%). Insider selling cluster ($2.2M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.9B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 11.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 30.3% to 13.4% (-16.9% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (13.4% > 10.0%), caution on chasing. MRS_5 (-4.8%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 12.9% shows strong absolute momentum above own 20MA. Outperforming sector by 13.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 13.41% (CS: 98) | Strong |
| RSI_14 | 63.6 | Neutral |
| MACD Histogram | 0.39 | Bullish |
| vs SMA20 | 1.129x | Above |
| vs SMA50 | 1.399x | Above |
| vs SMA200 | 2.557x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $64.66
- **Stop Loss:** $55.70 (13.9% risk)
- **Target:** $73.62 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 111
- **Position Value:** $7,177.26
- **Portfolio %:** 7.18%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*